Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash & Equivalents (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Cash & Equivalents for 12 consecutive years, with $34.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 15.75% year-over-year to $34.2 million, compared with a TTM value of $34.2 million through Sep 2025, down 15.75%, and an annual FY2024 reading of $38.1 million, up 121.61% over the prior year.
  • Cash & Equivalents was $34.2 million for Q3 2025 at CytomX Therapeutics, down from $49.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $329.7 million in Q1 2021 and bottomed at $17.2 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $108.2 million, with a median of $56.4 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 130.08% in 2021, then plummeted 91.13% in 2023.
  • Year by year, Cash & Equivalents stood at $205.5 million in 2021, then decreased by 5.78% to $193.6 million in 2022, then tumbled by 91.13% to $17.2 million in 2023, then surged by 121.61% to $38.1 million in 2024, then dropped by 10.16% to $34.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for CTMX at $34.2 million in Q3 2025, $49.0 million in Q2 2025, and $47.6 million in Q1 2025.